|
1.
|
Harrold L. New developments in gout. Curr Opin Rheumatol. 2013 May; 25(3):304-9.
|
|
|
|
|
2.
|
Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Lioté F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013 Apr; 40(4):498-505.
|
|
|
|
|
3.
|
Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, Solomon DH, Curtis JR, Lewis JD, Saag KG. Association between anti-TNF-a therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013 Apr; 22(4):394-402.
|
|
|
|
|
4.
|
Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, Gurwitz JH, Soumerai SB. Cost-related Medication Nonadherence in Older Patients with Rheumatoid Arthritis. J Rheumatol. 2013 Feb; 40(2):137-43.
|
|
|
|
|
5.
|
Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. Association between anti-TNF-a therapy and all-cause mortality. Pharmacoepidemiol Drug Saf. 2012 Dec; 21(12):1311-20.
|
|
|
|
|
6.
|
Tjia J, Field TS, Mazor KM, Donovan JL, Kanaan AO, Reed G, Doherty P, Harrold LR, Gurwitz JH. Dementia and risk of adverse warfarin-related events in the nursing home setting. Am J Geriatr Pharmacother. 2012 Oct; 10(5):323-30.
|
|
|
|
|
7.
|
Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood RA. Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord. 2012; 13(1):180.
|
|
|
|
|
8.
|
Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med. 2012 Sep; 125(9):937.e9-937.e15.
|
|
|
|
|
9.
|
Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord. 2012; 13:85.
|
|
|
|
|
10.
|
Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf. 2012 May; 21(5):524-34.
|
|
|
|
|
11.
|
Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar; 64(3):630-8.
|
|
|
|
|
12.
|
Chen Y, Harrold LR, Yood RA, Field TS, Briesacher BA. Identifying patients with osteoporosis or at risk for osteoporotic fractures. Am J Manag Care. 2012 Feb; 18(2):e61-7.
|
|
|
|
|
13.
|
Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul; 71(7):1134-42.
|
|
|
|
|
14.
|
Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:100-28.
|
|
|
|
|
15.
|
Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:129-40.
|
|
|
|
|
16.
|
Nitichaikulvatana P, Upchurch KS, Harrold LR. Impact of deficits in gout care on hospitalizations. J Clin Rheumatol. 2011 Oct; 17(7):389-91.
|
|
|
|
|
17.
|
Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
|
|
|
|
|
18.
|
Field TS, Tjia J, Mazor KM, Donovan JL, Kanaan AO, Harrold LR, Reed G, Doherty P, Spenard A, Gurwitz JH. Randomized Trial of a Warfarin Communication Protocol for Nursing Homes: an SBAR-based Approach. Am J Med. 2011 Feb; 124(2):179.e1-7.
|
|
|
|
|
19.
|
Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf. 2010 Dec; 19(12):1233-40.
|
|
|
|
|
20.
|
Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010 Dec; 6(4):263-71.
|
|
|
|
|
21.
|
Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med. 2010 Mar; 123(3):275-80.
|
|
|
|
|
22.
|
Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010 Jan 15; 62(1):101-7.
|
|
|
|
|
23.
|
Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, Ockene IS. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010 Jan; 123(1):54-9.
|
|
|
|
|
24.
|
Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 Jun; 48(6):686-90.
|
|
|
|
|
25.
|
Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009; 11(2):R46.
|
|
|
|
|
26.
|
Gurwitz JH, Field TS, Rochon P, Judge J, Harrold LR, Bell CM, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Baril JL, Reed G, Bates DW. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc. 2008 Dec; 56(12):2225-33.
|
|
|
|
|
27.
|
Harrold LR, Li W, Yood RA, Fuller J, Gurwitz JH. Identification of patients with arthritis and arthritis-related functional limitation using administrative data. J Public Health Manag Pract. 2008 Sep-Oct; 14(5):487-97.
|
|
|
|
|
28.
|
Harrold LR, Liu NY. Polyarteritis nodosa presenting as pancytopenia: case report and review of the literature. Rheumatol Int. 2008 Aug; 28(10):1049-51.
|
|
|
|
|
29.
|
Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009 Apr; 38(5):396-402.
|
|
|
|
|
30.
|
Harrold LR, Savageau JA, Pransky G, Benjamin K. Understanding the role of sex differences in work injuries: implications for primary care practice. Disabil Rehabil. 2008; 30(1):36-43.
|
|
|
|
|
31.
|
Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, Chan KA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R, Walker AM. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007 Jun; 16(6):620-6.
|
|
|
|
|
32.
|
Gurwitz JH, Field TS, Radford MJ, Harrold LR, Becker R, Reed G, DeBellis K, Moldoff J, Verzier N. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007 Jun; 120(6):539-44.
|
|
|
|
|
33.
|
Harrold LR, Saag KG, Yood RA, Mikuls TR, Andrade SE, Fouayzi H, Davis J, Chan KA, Raebel MA, Von Worley A, Platt R. Validity of gout diagnoses in administrative data. Arthritis Rheum. 2007 Feb 15; 57(1):103-8.
|
|
|
|
|
34.
|
Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006 Oct; 65(10):1368-72.
|
|
|
|
|
35.
|
Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother. 2006 Mar; 40(3):386-91.
|
|
|
|
|
36.
|
Harrold LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM, Chan KA, Frazier EA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol. 2005 Jun; 32(6):1076-80.
|
|
|
|
|
37.
|
Sciamanna CN, Harrold LR, Manocchia M, Walker NJ, Mui S. The effect of web-based, personalized, osteoarthritis quality improvement feedback on patient satisfaction with osteoarthritis care. Am J Med Qual. 2005 May-Jun; 20(3):127-37.
|
|
|
|
|
38.
|
Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Auger J, Bates DW. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005 Mar; 118(3):251-8.
|
|
|
|
|
39.
|
Sacks JJ, Harrold LR, Helmick CG, Gurwitz JH, Emani S, Yood RA. Validation of a surveillance case definition for arthritis. J Rheumatol. 2005 Feb; 32(2):340-7.
|
|
|
|
|
40.
|
Harrold LR, Andrade SE, Eisner M, Buist AS, Go A, Vollmer WM, Chan KA, Frazier EA, Weller PF, Wechsler ME, Davis KJ, Platt R. Identification of patients with Churg-Strauss syndrome (CSS) using automated data. Pharmacoepidemiol Drug Saf. 2004 Oct; 13(10):661-7.
|
|
|
|
|
41.
|
Field TS, Gurwitz JH, Harrold LR, Rothschild JM, Debellis K, Seger AC, Fish LS, Garber L, Kelleher M, Bates DW. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc. 2004 Nov-Dec; 11(6):492-8.
|
|
|
|
|
42.
|
Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, Auger JC, Garber LA, Cadoret C, Fish LS, Garber LD, Kelleher M, Bates DW. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004 Aug; 52(8):1349-54.
|
|
|
|
|
43.
|
Harrold LR, Esteban J, Lessard D, Yarzebski J, Gurwitz JH, Gore JM, Goldberg RJ. Narrowing gender differences in procedure use for acute myocardial infarction: insights from the Worcester heart attack study. J Gen Intern Med. 2003 Jun; 18(6):423-31.
|
|
|
|
|
44.
|
Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003 Mar 5; 289(9):1107-16.
|
|
|
|
|
45.
|
Harrold LR, Lessard D, Yarzebski J, Gurwitz JH, Gore JM, Goldberg RJ. Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community-wide perspective. Cardiology. 2003; 99(1):39-46.
|
|
|
|
|
46.
|
Harrold LR, Yood RA, Straus W, Andrade SE, Reed JI, Cernieux J, Lewis BE, Gurwitz JH. Challenges of estimating health service utilization for osteoarthritis patients on a population level. J Rheumatol. 2002 Sep; 29(9):1931-6.
|
|
|
|
|
47.
|
Harrold LR, Gurwitz JH, Tate JP, Becker R, Stuart T, Elwell A, Radford M. Physician attitudes concerning anticoagulation services in the long-term care setting. J Thromb Thrombolysis. 2002 Aug; 14(1):59-64.
|
|
|
|
|
48.
|
Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. Int J Cancer. 2001 Jul 1; 93(1):139-41.
|
|
|
|
|
49.
|
Yood RA, Harrold LR, Fish L, Cernieux J, Emani S, Conboy E, Gurwitz JH. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med. 2001 May 28; 161(10):1322-7.
|
|
|
|
|
50.
|
Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD, Yood RA. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med. 2000 Dec 11-25; 160(22):3401-5.
|
|
|
|
|
51.
|
Harrold LR, Yood RA, Andrade SE, Reed JI, Cernieux J, Straus W, Weeks M, Lewis B, Gurwitz JH. Evaluating the predictive value of osteoarthritis diagnoses in an administrative database. Arthritis Rheum. 2000 Aug; 43(8):1881-5.
|
|
|
|
|
52.
|
Harrold LR, Field TS, Gurwitz JH. Knowledge, patterns of care, and outcomes of care for generalists and specialists. J Gen Intern Med. 1999 Aug; 14(8):499-511.
|
|
|
|
|
53.
|
Rogers LR, Estes ML, Rosenbloom SA, Harrold L. Primary leptomeningeal oligodendroglioma: case report. Neurosurgery. 1995 Jan; 36(1):166-8; discussion 169.
|
|
|
|
